Vilin Bio Med Ltd (VILINBIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Vilin Bio Med Ltd on NSE and BSE, with an AI summary of each filing.
Vilin Bio Med Limited has informed the Exchange that, being listed on the NSE Emerge Platform, the Company is exempt from the applicable Corporate Governance requirements. However, the Company is voluntarily submitting the Integrated Corporate Governance Report for the period ended September 30, 2026.
Others (Uncategorized) · 27 Oct 2026, 6:51 pm
Vilin Bio Med Voluntarily Adopts Main Board Corporate Governance Reporting Standards Vilin Bio Med Limited submitted its Integrated Corporate Governance Report for the quarter ended 30th Sep'26 on a voluntary basis. Although listed on NSE Emerge and exempt under Regulation 15(2)(b) of SEBI LODR Regulations, the company adopted Main Board governance norms. The board confirmed full compliance across committee compositions, reported zero investor grievances, and noted no cyber security breaches during the period. Additionally, the filing affirmed 100% holdings in unlisted entities Axia Pharma Private Limited and Vilo Speciality Pharma Private Limited.
Vilin Bio Med Limited has submitted the Exchange a copy Srutinizers report of Court Convened General Meeting held on October 15, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 16 Oct 2026, 10:21 pm
Vilin Bio Med Shareholders and Creditors Approve Scheme of Amalgamation Vilin Bio Med Limited announced that equity shareholders and unsecured creditors unanimously approved the Scheme of Amalgamation with Chemgenix Laboratories Private Limited during NCLT-convened meetings on 15th Oct'26. According to the Scrutinizer’s report, 100% of the 24,83,085 equity votes polled (representing 16.28% of total outstanding shares) voted in favor of the special resolution, with zero dissenting votes. Additionally, Evexia Lifecare Limited, representing 100% of voting unsecured creditor debt valued at Rs. 13.93 cr, voted in favor, clearing a major hurdle for the merger.
Vilin Bio Med Limited has informed the Exchange regarding Proceedings of Court Convened General Meeting held on October 15, 2026
Annual General Meeting · 15 Oct 2026, 8:00 pm
Vilin Bio Med Convenes NCLT-Directed Meetings for Chemgenix Laboratories Merger Pursuant to the NCLT Hyderabad Bench-I order dated 10th Sep'26, Vilin Bio Med Limited convened separate meetings of its equity shareholders and unsecured creditors on 15th Oct'26. The meetings were held to consider and approve the proposed Scheme of Amalgamation of Chemgenix Laboratories Private Limited into Vilin Bio Med Limited under Sections 230 to 232 of the Companies Act, 2013. Remote e-voting and venue voting facilities were provided, and final voting results will be disclosed upon receipt of the scrutinizer’s report.
Vilin Bio Med Limited has informed the Exchange regarding Outcome of Board Meeting held on September 15, 2026.
Outcome · 16 Sept 2026, 12:02 am
Vilin Bio Med Convenes NCLT-Directed Meetings for Chemgenix Laboratories Merger Pursuant to the NCLT Hyderabad Bench-I order dated 10th Sep'26, Vilin Bio Med Limited has convened meetings of its equity shareholders and creditors on 15th Oct'26 to approve the Scheme of Amalgamation with Chemgenix Laboratories Private Limited. The share swap ratio is fixed at 1:1, requiring the issuance of 96.90 lakh shares. Consequently, post-merger equity will increase to 2.49 crore shares, raising promoter holding from 56.65% to 73.49% and diluting public shareholding to 26.51%. Remote e-voting runs from 12th Oct'26 to 14th Oct'26.
Vilin Bio Med Limited has informed the Exchange regarding 'General Updates'.
Others (Uncategorized) · 15 Sept 2026, 6:51 pm
Vilin Bio Med Confirms Ongoing Merger Process with Chemgenix Laboratories Vilin Bio Med Limited confirmed that the proposed Scheme of Arrangement for the amalgamation of Chemgenix Laboratories Private Limited into the company is complying with NCLT directions dated 10th Sep'26. Upon securing in-principle approval from the NSE, both entities will formally apply to the NCLT for final sanction. The scheme will be executed following statutory approvals under the Companies Act, 2013 and adherence to terms prescribed by the NSE and NCLT.
Vilin Bio Med Limited has informed the Exchange regarding 'General Updates'.
Others (Uncategorized) · 15 Sept 2026, 6:48 pm
Vilin Bio Med Confirms Compliance for Chemgenix Laboratories Merger Scheme Vilin Bio Med Limited confirmed that its proposed Scheme of Arrangement for the amalgamation of Chemgenix Laboratories Private Limited into the company complies with applicable laws, prescribed Accounting Standards, and regulatory frameworks under SEBI LODR Regulation 37. The merger adheres to Sections 230–232 of the Companies Act, 2013, following directions from the NCLT order dated 10th Sep'26. The scheme will become effective upon receiving all requisite statutory and regulatory approvals from authorities.
VILIN BIO MED LIMITED has informed the Exchange about Board Meeting to be held on 15-Sep-2026 to consider Amalgamation.
Intimation · 12 Sept 2026, 1:21 am
Vilin Bio Med Board to Consider Amalgamation Proposal on 15th Sep'26 Vilin Bio Med Limited announced that a meeting of its Board of Directors is scheduled for 15th Sep'26 to consider a proposal for amalgamation. The potential corporate restructuring remains subject to requisite approvals from the board, regulatory authorities, and shareholders.
VILINBIO : 15-Sep-2026 : The Company has informed the Exchange that a Board meeting to be held on September 18, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on September 15, 2026, To consider other business matters
Intimation · 12 Sept 2026, 1:14 am
Vilin Bio Med Reschedules Board Meeting to 15th Sep'26 Vilin Bio Med Limited has rescheduled its Board of Directors meeting from 18th Sep'26 to 15th Sep'26 to consider matters incidental to a proposed Scheme alongside other business. Consequently, pursuant to SEBI Insider Trading Regulations, the trading window for dealing in company securities remains closed for designated persons and their immediate relatives from 11th Sep'26 until 48 hours post-conclusion of the board meeting.
VILIN BIO MED LIMITED has informed the Exchange about Board Meeting to be held on 18-Sep-2026 to consider Amalgamation.
Intimation · 11 Sept 2026, 10:55 pm
Vilin Bio Med Board to Consider Amalgamation on 18th Sep'26 Vilin Bio Med Limited has informed the exchange that a meeting of its Board of Directors is scheduled for 18th Sep'26. The board will convene primarily to consider and evaluate a proposal for amalgamation, marking a potentially significant corporate restructuring event for the company.
VILIN BIO MED LIMITED has informed the Exchange about Board Meeting to be held on 18-Sep-2026 to consider Amalgamation.
Intimation · 11 Sept 2026, 10:54 pm
Vilin Bio Med Schedules Board Meeting to Consider Amalgamation Proposal Vilin Bio Med Limited has scheduled a meeting of its Board of Directors on 18th Sep'26 to evaluate and consider a proposal for amalgamation.
To consider other business matters
Intimation · 11 Sept 2026, 10:45 pm
Vilin Bio Med Board to Consider Chemgenix Laboratories Merger Vilin Bio Med Limited scheduled a Board of Directors meeting on 18th Sep'26 to consider and approve a proposed Scheme of Amalgamation with Chemgenix Laboratories Private Limited (Transferee Company), where Vilin Bio Med will act as the Transferor Company, subject to regulatory approvals. In compliance with insider trading regulations, the trading window for dealing in company securities is closed for Designated Persons and their immediate relatives from 11th Sep'26 until 48 hours post-conclusion of the board meeting.
Vilin Bio Med Limited has informed the Exchange about Amalgamation/Merger
Others · 11 Sept 2026, 8:44 pm
NCLT Approves Scheme Application for Vilin Bio Med and Chemgenix Merger NCLT Hyderabad Bench-I, via order dated 10th Sep'26, allowed the first-stage joint scheme application for the merger by absorption of Chemgenix Laboratories Private Limited into Vilin Bio Med Limited. The tribunal dispensed with the meeting of Chemgenix's equity shareholders following 100% consent. It directed convening meetings of Chemgenix's creditors, alongside public shareholders and unsecured creditors of Vilin Bio Med, on 15th Oct'26. The share exchange ratio is set at 1:1, offering 1 equity share of Vilin Bio Med (Rs.10 each) for every 1 share of Chemgenix.
Scrutinizer Report and Voting Results
Annual General Meeting · 03 Sept 2026, 10:11 pm
Vilin Bio Med 20th AGM: All 9 Resolutions Passed with 100% Majority Vilin Bio Med shareholders passed all nine resolutions with 100% approval at the 20th AGM on 2nd Sep'26. Total voter turnout was 55.99%, comprising 8,539,244 shares. Key equity-relevant approvals include raising borrowing limits beyond paid-up capital and free reserves, creating charges on company assets, and authorizing loans and investments under Sections 185/186. Additionally, shareholders unanimously approved material related-party transactions with wholly-owned subsidiaries Vilo Speciality Pharma and Axia Pharma. Finally, the FY26 audited financial statements were adopted, and Ms. Prasanna Lakshmi Venna was re-appointed as Director.
Vilin Bio Med Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 02, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 03 Sept 2026, 6:28 pm
Vilin Bio Med Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 02, 2026
Annual General Meeting · 02 Sept 2026, 10:30 pm
Vilin Bio Med Limited has informed the Exchange about General Updates
Others (Uncategorized) · 11 Aug 2026, 8:14 pm
Vilin Bio Med Limited has informed the Exchange regarding Outcome of Board Meeting held on August 10, 2026.
Outcome · 10 Aug 2026, 8:58 pm
Vilin Bio Med Appoints New Secretarial Auditor, Sets AGM for Sep'26 Vilin Bio Med's board, on 10 Aug'26, appointed M/s Pawan Jain & Associates as Secretarial Auditors for five years, replacing Mr. Kashinath Sahu who resigned. The firm's 20th Annual General Meeting (AGM) is scheduled for 02 Sep'26 via video conference to approve this appointment and the FY26 financials. The cut-off date for AGM voting eligibility is 26 Aug'26, with the remote e-voting window open from 30 Aug'26 to 01 Sep'26. The new auditor appointment extends from FY27 to FY31.
Vilin Bio Med Limited has informed the Exchange regarding ' Vilin Bio Med Limited has informed the Exchange regarding Updates'.
Others (Uncategorized) · 01 Aug 2026, 11:34 pm
Vilin Bio Med Registers as "Manufacturer Exporter" with Pharmexcil Vilin Bio Med announced on 1 Aug'26 its registration as a "Manufacturer Exporter" with the Pharmaceuticals Export Promotion Council of India (Pharmexcil). Management expects this to enhance global visibility, strengthen partner relationships, and facilitate expansion into new international export markets. This development aligns with the company's long-term growth and business expansion strategy by enabling direct B2B interactions with overseas buyers, potentially boosting its export revenues.
Vilin Bio Med Limited has informed the Exchange about General Updates
Others (Uncategorized) · 29 Jul 2026, 8:45 pm
Vilin Bio Med Signs MOU with Ideal Pharma for European Distribution Vilin Bio Med signed a Memorandum of Understanding (MOU) on 29 Jul'26 with Netherlands-based Ideal Pharma BV. The agreement establishes a collaboration for the distribution of generic and branded medicines across Europe, leveraging Ideal Pharma's established wholesale infrastructure. This strategic move aims to expand Vilin Bio Med's market access for its pharmaceutical and healthcare products. The MOU is non-binding, with definitive agreements to be executed later, and does not involve any equity exchange, special rights, or related party transactions.
Vilin Bio Med Limited has informed the Exchange about General Updates
Others (Uncategorized) · 15 Jul 2026, 12:02 am
Vilin Bio Med to Incorporate Two Wholly-Owned Pharmaceutical Subsidiaries Vilin Bio Med is incorporating two wholly-owned subsidiaries, "Vilo Speciality Pharma Private Limited" and "Axia Pharma Private Limited," as per a Jul 14, '26 filing. Both entities will operate in the pharmaceutical industry with an authorised capital of ₹10 lakh each. Vilo Speciality Pharma will focus on marketing and distribution of oncology and specialty products. Axia Pharma will focus on marketing and distribution of generic pharmaceutical products, APIs, and other medicines. Both are pre-revenue entities with operations yet to commence.
Vilin Bio Med Limited has informed the Exchange regarding ''Non-applicability of Corporate Governance Regulations to the Company."
Others (Uncategorized) · 10 Jul 2026, 11:08 pm
Vilin Bio Med States Non-Applicability of Corporate Governance Report Vilin Bio Med Limited (NSE: VILINBIO) announced on Jul 10, '26, that Corporate Governance provisions under SEBI's Listing Regulations are not applicable for the quarter ended Jun 30, '26. The company cited its listing on the NSE's SME Platform, which provides an exemption under Regulation 15(2)(b) of the SEBI (LODR) Regulations, 2015. Consequently, compliance with Regulations 17 to 27 and other specified clauses related to corporate governance is not required for the company.
Vilin Bio Med Limited has informed the Exchange about Resignation of Director/KMP/SMP
Change in Management · 27 Jun 2026, 11:20 pm
VILINBIO: Vilin Bio Med Limited has informed the Exchange regarding Outcome of Board Meeting held on June 27, 2026.
Outcome · 27 Jun 2026, 10:56 pm
Vilin Bio Med Appoints New Company Secretary Amid Management Reshuffle Vilin Bio Med's Board announced key management changes from its meeting on 27 Jun'26. The company appointed Ms. Neha Lahoti as the new Company Secretary and Compliance Officer, effective immediately. This follows the resignation of the previous officer, Ms. Anjali Choudhary, who stepped down for personal reasons on the same day. Ms. Lahoti is an Associate Member of ICSI with experience in corporate laws and SEBI regulations. The transition marks a notable change in the company's key compliance personnel.